Advertisement
Advertisement
ADCT
ADC Therapeutics SA
3.48
USDSponsored
+0.05
+1.46%
May 13, 16:00 UTC -4
Closed
Pre-Market
3.55
+0.07
+2.01%
ADCT Earnings Reports
Positive Surprise Ratio
ADCT beat 15 of 24 last estimates.
63%
Next Report
Date of Next Report
Aug 10, 2026
Estimate for Q2 26 (Revenue/ EPS)
$19.97M
/-$0.21
Implied change from Q1 26 (Revenue/ EPS)
-4.20%
/+61.54%
Implied change from Q2 25 (Revenue/ EPS)
+6.03%
/-44.74%
ADC Therapeutics SA earnings per share and revenue
On May 04, 2026, ADCT reported earnings of -0.13 USD per share (EPS) for Q1 26, beating the estimate of -0.21 USD, resulting in a 40.72% surprise. Revenue reached 20.85 million, compared to an expected 19.62 million, with a 6.25% difference. The market reacted with a -3.92% price change (close before vs. close after earnings).
Looking ahead to Q2 26, 4 analysts forecast an EPS of -0.21 USD, with revenue projected to reach 19.97 million USD, implying an increase of 61.54% EPS, and decrease of -4.20% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Kamada Ltd
Report Date
May 13, 2026 For Q1 26
Estimate
$0.11
Actual
$0.07
Surprise
-40.32%
Abeona Therapeutics Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.36
Actual
-$0.30
Surprise
+17.31%
Milestone Pharmaceuticals Inc. Common Shares
Report Date
May 13, 2026 For Q1 26
Estimate
$0.31
Actual
-$0.20
Surprise
-163.94%
Spero Therapeutics, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.18
Actual
-$0.13
Surprise
+29.19%
Equillium, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.04
Actual
-$0.06
Surprise
-34.53%
Spruce Biosciences, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$8.99
Actual
-$8.94
Surprise
+0.58%
BeyondSpring Inc. Ordinary Shares
Report Date
May 13, 2026 For Q1 26
Estimate
-Actual
-$0.05
Surprise
-
Tango Therapeutics, Inc.
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.31
Actual
-$0.32
Surprise
-0.13%
Longeveron Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.16
Actual
-$0.19
Surprise
-12.89%
Bionano Genomics, Inc. Common Stock
Report Date
May 13, 2026 For Q1 26
Estimate
-$0.96
Actual
-$0.76
Surprise
+21.57%
FAQ
What were ADC Therapeutics SA's earnings and revenue for the latest quarter Q1 2026?
For Q1 2026, ADC Therapeutics SA reported EPS of -$0.13, beating estimates by 40.72%, and revenue of $20.85M, 6.25% above expectations.
How did the market react to ADC Therapeutics SA's Q1 2026 earnings?
The stock price moved down -3.92%, changed from $3.83 before the earnings release to $3.68 the day after.
When is ADC Therapeutics SA expected to report next?
The next earning report is scheduled for Aug 10, 2026.
What are the forecasts for ADC Therapeutics SA's next earnings report?
Based on 4
analysts, ADC Therapeutics SA is expected to report EPS of -$0.21 and revenue of $19.97M for Q2 2026.
Which companies are reporting earnings today?
Check FXEmpire's Earnings Calendar for today's list of reporting companies.
Advertisement